title: Effect of a competitive inhibitor of platelet aggregation on experimentally induced laminitis in ponies.
abstract: OBJECTIVE
  To determining whether inhibition of platelet aggregation prevents development of carbohydrate overload-induced alimentary laminitis.
  
  
  METHODS
  22 healthy adult ponies.
  
  
  METHODS
  Acute laminitis was induced by oral administration of corn starch/wood flour to 16 ponies, 8 of which were treated with a synthetic analogue of the platelet fibrinogen receptor antagonist peptide (RPR) RGDS (arginine-glycine-aspartic acid-serine) 110885; 6 ponies served as negative controls. Blood was collected before and at 4, 8, 12, 24, 28, and 32 hours after administration of carbohydrate overload, and PCV, total plasma protein concentration, platelet count, activated clotting time, whole blood recalcification time, spontaneous platelet aggregation, ex vivo platelet aggregation responses, in vivo platelet activation, and platelet-neutrophil aggregates were evaluated.
  
  
  RESULTS
  Of 16 ponies given carbohydrate, 6 of 8 untreated ponies developed laminitis and 0 of 8 ponies treated with RPR 110885 developed laminitis. The RPR 110885 treatment attenuated the increase in platelet-neutrophil aggregates observed in untreated ponies.
  
  
  CONCLUSIONS
  Platelets are involved in the pathogenesis of equine alimentary laminitis.
  
  
  CONCLUSIONS
  Platelet aggregation inhibitors may be useful for prevention or treatment of laminitis, or both.
authors.affiliation: Department of Veterinary PathoBiology, College of Veterinary Medicine, University of Minnesota, St Paul 55108, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Weiss
authors.forename: O A
authors.initials: OA
authors.lastname: Evanson
authors.forename: D
authors.initials: D
authors.lastname: McClenahan
authors.forename: J J
authors.initials: JJ
authors.lastname: Fagliari
authors.forename: C T
authors.initials: CT
authors.lastname: Dunnwiddie
authors.forename: R E
authors.initials: RE
authors.lastname: Wells
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D005260:Female; D005534:Foot Diseases / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D006734:Horse Diseases / Q000097:blood / Q000188:drug therapy*; D006736:Horses; D007794:Lameness, Animal / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D009842:Oligopeptides / Q000627:therapeutic use*; D010974:Platelet Aggregation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count / Q000187:drug effects; D014934:Wood; D003313:Zea mays
chemical_list: D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; C046617:arginyl-glycyl-aspartyl-serine